**Assets available for partnering or sale**

The following assets have been de-prioritized in our portfolio, and we would welcome a discussion with interested parties:

<table>
<thead>
<tr>
<th>Asset</th>
<th>Target</th>
<th>Modality</th>
<th>Stage</th>
<th>Therapeutic area</th>
</tr>
</thead>
<tbody>
<tr>
<td>SYM015/S95027</td>
<td>MET receptor</td>
<td>Monoclonal antibody</td>
<td>Phase 2</td>
<td>Oncology</td>
</tr>
<tr>
<td>SYM029/ONC0084</td>
<td>CD40 agonist</td>
<td>Monoclonal antibody</td>
<td>Lead optimisation</td>
<td>Oncology</td>
</tr>
<tr>
<td>RHU030</td>
<td>Galectin-3</td>
<td>Monoclonal antibody</td>
<td>Lead optimisation</td>
<td>Immuno-Inflammatory</td>
</tr>
</tbody>
</table>

If interested please fill in the **on-line form** and a member of Global Business Development will respond.
**Partnering with Servier**

Partnership is embedded in our culture with highly engaged and diverse teams partnering for a shared purpose - contributing to therapeutic progress to serve patient needs. Our partnership approach serves one goal: to bring life-changing treatments to patients faster. We strive to always put patients first, leading to better outcomes for ourselves and our partners.

**A partner of choice**

**A partner with strong commitment**

Servier is an independent pharmaceutical company committed to therapeutic progress to serve patient needs. Its unique governance allows Servier to reinvest all its profits to support its development, as well as plan and invest with a long-term view, in line with its vocation. Servier long-term vision applies to its partnership philosophy.

**A partner with a global presence**

With €4.98bn of revenue in 2022 across 150 countries worldwide, the Group has a growing presence in the USA and Japan, a strong EU presence and a deep knowledge of emerging countries and China.

**A partner with proven expertise and experience**

Servier is very focused on specialty care oncology with a proven expertise of over 60 years in cardiovascular and metabolic diseases. It is developing new therapeutic solutions to serve unmet patient needs. From R&D to commercialization, we have proven experience to help new therapeutic innovations become reality for patients, alone or with partners.

**A partner you can rely on**

Servier is proud of what has been achieved with its partners so far. Servier has a strong track record of providing flexible partnership structures to its many partners, as well as an R&D infrastructure with 2,900 people in France, Hungary and Boston and an extensive commercial knowledge of global markets.

---

### Partnering interests

#### Oncology

**Discovery & Early Clinical Focus**
- Cancer cell Targeting
  - Synthetic lethality
  - Apoptosis
  - Precision oncology
  - Epigenetic regulators

**Late-stage Clinical Focus**
- Hematologic tumors (NHL, ALL, AML)

#### Immuno-oncology

- Tumor micro-environment
- T cell targeting
- Antibodies, Bispecifics, ADCs

#### Immuno-inflammation

- Autoantibody-driven autoimmune diseases
- And other diseases sharing similar pathophysiological mechanisms

#### Neuroscience

- Hereditary forms of Parkinson Disease
- Rare neurological disorders including:
  - Multiple System Atrophy
  - Familial Amyotrophic Lateral Sclerosis
  - Spinocerebellar Ataxia
  - Progressive Supranuclear Palsy
  - Genetically driven paediatric epilepsias

#### Cardiovascular & Metabolism diseases

- Acquire or license market-ready or mature assets for some geographies